Atara Biotherapeutics, Inc. Insider Trading

ATRA

⊜ Compare

Last 12 months

Insiders bought 1000K and sold 688K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

+312K

1 buy · 8 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 3

executives and directors

Last open-market buy

Sep 2026

Sep 4, 2026

Get an email when ATRA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 4	Brian N Cherry Director	Bought	104,166	$9.60	1000K	167%	Form 4
Aug 17	Anhco Nguyen President and CEO	SoldNo plan	5,062	$8.08	41K	3.7%	Form 4
May 18	Anhco Nguyen President and CEO	SoldNo plan	5,241	$9.13	48K	3.7%	Form 4
May 18	Yanina Grant-Huerta Chief Accounting Officer	SoldNo plan	2,414	$9.13	22K	4.6%	Form 4
May 7	Panacea Innovation Ltd Large holder	SoldNo plan	313,446	$10.10	$3.17M	19%	Form 4
May 7	Ecor1 Capital, LLC Large holder	Bought	507,407	$9.35	$4.74M	49%	Form 4
Mar 2	Yanina Grant-Huerta Chief Accounting Officer	SoldNo plan 4 parts	2,104	$5.08 average	11K	6.2%	Form 4
Mar 2	Anhco Nguyen President and CEO	SoldNo plan 4 parts	2,996	$5.09 average	15K	4.6%	Form 4
Jan 12	James Huang Director	SoldNo plan	80,554	$6.07	489K	5.7%	Form 4
Nov 17, 2025	Anhco Nguyen President and CEO	SoldNo plan 2 parts	2,915	$13.19 average	38K	4.3%	Form 4
Nov 17, 2025	Yanina Grant-Huerta Chief Accounting Officer	SoldNo plan 3 parts	1,804	$13.19 average	24K	5.1%	Form 4
Aug 18, 2025	Anhco Nguyen President and CEO	SoldNo plan 3 parts	2,958	$11.62 average	34K	4.2%	Form 4
Aug 18, 2025	Yanina Grant-Huerta Chief Accounting Officer	SoldNo plan 3 parts	1,809	$11.61 average	21K	4.9%	Form 4
Aug 15, 2025	Panacea Innovation Ltd Large holder	Bought	55,000	$12.19	670K	4.1%	Form 4
Jul 17, 2025	James Huang Director	Bought	19,335	$9.64	186K	1.5%	Form 4
May 16, 2025	Yanina Grant-Huerta Chief Accounting Officer	SoldNo plan	2,218	$6.76	15K	5.6%	Form 4
May 16, 2025	Anhco Nguyen President and CEO	SoldNo plan	3,276	$6.76	22K	4.4%	Form 4
Mar 3, 2025	Anhco Nguyen President and CEO	SoldNo plan	3,331	$7.00	23K	4.3%	Form 4
Mar 3, 2025	Eric J Hyllengren EVP, CFO and COO	SoldNo plan	1,211	$7.00	8K	2.1%	Form 4
Mar 3, 2025	Jill Henrich EVP, Chief Regulatory Officer	SoldNo plan	1,059	$7.00	7K	5.4%	Form 4
Nov 18, 2024	Jill Henrich EVP, Chief Regulatory Officer	SoldNo plan	1,000	$11.20	11K	4.9%	Form 4
Nov 18, 2024	Eric J Hyllengren EVP, CFO and COO	SoldNo plan	1,364	$11.20	15K	5.5%	Form 4
Nov 18, 2024	Anhco Nguyen President and CEO	SoldNo plan	1,664	$11.20	19K	2.1%	Form 4

Sep 4
Brian N Cherry
Director · bought 104,166 at $9.60
1000K
167% of stake
Aug 17No plan
Anhco Nguyen
President and CEO · sold 5,062 at $8.08
41K
3.7% of stake
May 18No plan
Anhco Nguyen
President and CEO · sold 5,241 at $9.13
48K
3.7% of stake
May 18No plan
Yanina Grant-Huerta
Chief Accounting Officer · sold 2,414 at $9.13
22K
4.6% of stake
May 7No plan
Panacea Innovation Ltd
Large holder · sold 313,446 at $10.10
$3.17M
19% of stake
May 7
Ecor1 Capital, LLC
Large holder · bought 507,407 at $9.35
$4.74M
49% of stake
Mar 2No plan
Yanina Grant-Huerta
Chief Accounting Officer · sold 2,104 at avg $5.08
11K
6.2% of stake
Mar 2No plan
Anhco Nguyen
President and CEO · sold 2,996 at avg $5.09
15K
4.6% of stake
Jan 12No plan
James Huang
Director · sold 80,554 at $6.07
489K
5.7% of stake
Nov 17, 2025No plan
Anhco Nguyen
President and CEO · sold 2,915 at avg $13.19
38K
4.3% of stake
Nov 17, 2025No plan
Yanina Grant-Huerta
Chief Accounting Officer · sold 1,804 at avg $13.19
24K
5.1% of stake
Aug 18, 2025No plan
Anhco Nguyen
President and CEO · sold 2,958 at avg $11.62
34K
4.2% of stake
Aug 18, 2025No plan
Yanina Grant-Huerta
Chief Accounting Officer · sold 1,809 at avg $11.61
21K
4.9% of stake
Aug 15, 2025
Panacea Innovation Ltd
Large holder · bought 55,000 at $12.19
670K
4.1% of stake
Jul 17, 2025
James Huang
Director · bought 19,335 at $9.64
186K
1.5% of stake
May 16, 2025No plan
Yanina Grant-Huerta
Chief Accounting Officer · sold 2,218 at $6.76
15K
5.6% of stake
May 16, 2025No plan
Anhco Nguyen
President and CEO · sold 3,276 at $6.76
22K
4.4% of stake
Mar 3, 2025No plan
Anhco Nguyen
President and CEO · sold 3,331 at $7.00
23K
4.3% of stake
Mar 3, 2025No plan
Eric J Hyllengren
EVP, CFO and COO · sold 1,211 at $7.00
8K
2.1% of stake
Mar 3, 2025No plan
Jill Henrich
EVP, Chief Regulatory Officer · sold 1,059 at $7.00
7K
5.4% of stake
Nov 18, 2024No plan
Jill Henrich
EVP, Chief Regulatory Officer · sold 1,000 at $11.20
11K
4.9% of stake
Nov 18, 2024No plan
Eric J Hyllengren
EVP, CFO and COO · sold 1,364 at $11.20
15K
5.5% of stake
Nov 18, 2024No plan
Anhco Nguyen
President and CEO · sold 1,664 at $11.20
19K
2.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ATRA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ATRA

CompareIntrinsic value

FATEFate Therapeutics Inc.

$2.09+2.45%10

TSHATaysha Gene Therapies Inc.

$4.36+6.60%40

ZEOXZeo Scientifix Inc.

$0.97+0.00%25

CRISCuris Inc.

$1.11+56.34%25

CGONCG Oncology, Inc.

$67.71+5.70%40

DBVTDBV Technologies S.A.

$9.94-1.68%10

SRZNSurrozen, Inc.

$31.65+5.08%10

PRMEPrime Medicine Inc.

$4.97+9.23%0

Spot a number that looks wrong? Check it in ATRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ATRA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.